SB17: relative to treatment for hepatitis C under the law relative to use of cannabis for therapeutic purposes.

CHAPTER 146

SB 17 - FINAL VERSION

2017 SESSION

17-0765

01/09

SENATE BILL 17

AN ACT relative to treatment for hepatitis C under the law relative to use of cannabis for therapeutic purposes.

SPONSORS: Sen. Reagan, Dist 17

COMMITTEE: Health and Human Services

ANALYSIS

This bill clarifies hepatitis C as a qualifying medical condition for the use of cannabis for therapeutic purposes.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

17-0765

01/09

STATE OF NEW HAMPSHIRE

In the Year of Our Lord Two Thousand Seventeen

AN ACT relative to treatment for hepatitis C under the law relative to use of cannabis for therapeutic purposes.

Be it Enacted by the Senate and House of Representatives in General Court convened:

146:1 Use of Cannabis for Therapeutic Purposes; Definitions. Amend RSA 126-X:1, IX(a)(1) to read as follows:

(1) Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, hepatitis C [currently receiving antiviral treatment], amyotrophic lateral sclerosis, muscular dystrophy, Crohn's disease, multiple sclerosis, chronic pancreatitis, spinal cord injury or disease, traumatic brain injury, epilepsy, lupus, Parkinson's disease, Alzheimer's disease, ulcerative colitis, or one or more injuries that significantly interferes with daily activities as documented by the patient's provider; and

146:2 Effective Date. This act shall take effect upon its passage.

Approved: June 16, 2017

Effective Date: June 16, 2017